NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Lokness who wrote (512)	6/26/1999 5:42:00 PM
From: Mike McFarland	of 613

PS I should point out that there is certainly some competition out there... recap.com that query gives one the impression that Genetic Therapy, Human Genome Sciences, Vical, Transkaryotic Therapies, Transgene, and Cell Genesys are pretty big players. A treatment for CF and EPO production will probably be the first two big successes from gene therapy. I should have considered my rant about the public's perception of the area of Gene Therapy a bit more before I typed: Obviously the public has no opinion on the subject. (And biotech is going to march along regardless.) If you asked ten people off the street what genes are and what they do, you would not get a correct answer-- heck, I myself am only moving on to biotech investing 201 this year!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next